US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter of 2024, with revenues reaching USD 8.5 billion, an increase of 23% year-on-year (YOY). Product sales saw a 24% increase, with an 8% growth when excluding sales from the Horizon Therapeutics (Horizon) acquisition.
In the third quarter, ten of Amgen’s products achieved double-digit sales growth. Repatha (evolocumab), a treatment for high cholesterol, recorded sales of USD 567 million, up 40%. Tezspire (tezepelumab-ekko), a therapy for asthma and COPD, saw sales of USD 269 million, an increase of 67%. Blincyto (blinatumomab), used for lymphoma and leukemia, reported sales of USD 327 million, up 49%. Evenity (romosozumab-aqqg), an osteoporosis drug, had sales of USD 399 million, a 30% increase. Tavneos (avacopan), an adjuvant therapy for vasculitis, generated USD 80 million, marking a significant increase of 116%.
Amgen’s rare disease products contributed USD 1.2 billion in sales, driven by first-in-class and early-in-lifecycle medicines such as Tepezza, Krystexxa, Uplizna, and Tavneos. All are Horizon-acquired assets except for Tavneos.- Flcube.com
